{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T17:58:17Z","timestamp":1781114297983,"version":"3.54.1"},"reference-count":30,"publisher":"SAGE Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JRS"],"published-print":{"date-parts":[[2022,2,22]]},"abstract":"<jats:p>BACKGROUND: The majority of antidepressants inhibit serotonin reuptake and include the selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and the serotonin reuptake inhibiting tricyclic antidepressants. OBJECTIVE: The objective of this study was to investigate and describe the range and impact of reported adverse visual effects linked to serotonin reuptake inhibiting antidepressants. METHODS: Using data from a global database of patient spontaneous reports of drug adverse events, we systematically identified eligible reports of visual problems linked to the use of serotonin reuptake inhibiting antidepressants. We analyzed these data using simple descriptive statistics to present the range and impact. RESULTS: We identified 124 reports of visual problems. Reports originate from 18 countries and involve 11 different drugs. The most commonly reported symptoms were vision blurred\/visual acuity reduced (n =\u00a079, 63.7%), night blindness (n =\u00a022, 17.7%), vitreous floaters (n =\u00a021, 16.9%), photophobia (n =\u00a019, 15.3%), diplopia (n =\u00a015, 12.1%), palinopsia (n =\u00a013, 10.5%), visual field defect (n =\u00a012, 9.7%), photopsia (n =\u00a011, 8.9%) and visual snow syndrome (n =\u00a011, 8.9%). 74 patients indicated that the side effect was bad enough to affect everyday activities, 62 had sought health care, and 50 indicated that their work had been affected. 49 patients reported an enduring vision problem after discontinuation of treatment. CONCLUSIONS: The data suggest that serotonin reuptake inhibiting antidepressants can produce a range of adverse effects on vision that in some cases can be long-lasting after discontinuation of the drug. Further efforts are needed to understand the mechanisms involved, the incidence among those prescribed these medications, and identify any risk or mitigation factors.<\/jats:p>","DOI":"10.3233\/jrs-210018","type":"journal-article","created":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T13:06:02Z","timestamp":1628255162000},"page":"37-47","source":"Crossref","is-referenced-by-count":21,"title":["Development and persistence of patient-reported visual problems associated with serotonin reuptake inhibiting antidepressants"],"prefix":"10.1177","volume":"33","author":[{"given":"David","family":"Healy","sequence":"first","affiliation":[{"name":", McMaster University, , , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dee","family":"Mangin","sequence":"additional","affiliation":[{"name":", McMaster University, , , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Lochhead","sequence":"additional","affiliation":[{"name":", St Mary\u2019s Hospital, , , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"issue":"283","key":"10.3233\/JRS-210018_ref1","first-page":"1","article-title":"Antidepressant use among persons aged 12 and over: United States, 2011\u20132014","author":"Pratt","year":"2017","journal-title":"NCHS Data Brief"},{"issue":"6","key":"10.3233\/JRS-210018_ref2","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.ophtha.2009.11.042","article-title":"Selective serotonin reuptake inhibitors and the risk of cataracts: a nested case-control study","volume":"117","author":"Etminan","year":"2010","journal-title":"Ophthalmology"},{"issue":"1","key":"10.3233\/JRS-210018_ref3","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ajo.2014.03.006","article-title":"Selective serotonin reuptake inhibitor use and increased risk of cataract surgery: A population-based, case-control study","volume":"158","author":"Erie","year":"2014","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.3233\/JRS-210018_ref4","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1016\/j.jcjo.2014.06.005","article-title":"Case of rapid bilateral cataract development in teenager using selective serotonin reuptake inhibitors","volume":"49","author":"Kisilevsky","year":"2014","journal-title":"Can J Ophthalmol"},{"key":"10.3233\/JRS-210018_ref5","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jad.2017.03.044","article-title":"Antidepressants and risk of cataract development: A population-based, nested case-control study","volume":"215","author":"Chou","year":"2017","journal-title":"J Affect Disord"},{"issue":"9","key":"10.3233\/JRS-210018_ref6","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/eye.2015.119","article-title":"SSRI-associated optic neuropathy","volume":"29","author":"Lochhead","year":"2015","journal-title":"Eye (Lond)"},{"issue":"4","key":"10.3233\/JRS-210018_ref7","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1034\/j.1600-0420.2001.079004428.x","article-title":"Presumed sertraline maculopathy","volume":"79","author":"Sener","year":"2001","journal-title":"Acta Ophthalmol Scand"},{"issue":"6","key":"10.3233\/JRS-210018_ref8","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1177\/1039856214556327","article-title":"Bilateral maculopathy associated with sertraline","volume":"22","author":"Ewe","year":"2014","journal-title":"Australas Psychiatry"},{"issue":"2","key":"10.3233\/JRS-210018_ref9","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/ICB.0000000000000115","article-title":"Bull\u2019s eye maculopathy in a patient taking sertraline","volume":"9","author":"Mason","year":"2015","journal-title":"Retin Cases Brief Rep"},{"key":"10.3233\/JRS-210018_ref10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ajoc.2018.06.021","article-title":"Bilateral cystoid macular edema misdiagnosed as pars planitis in a patient on sertraline therapy","volume":"11","author":"Agarwal","year":"2018","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"1","key":"10.3233\/JRS-210018_ref12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1176\/appi.psy.46.1.91","article-title":"Citalopram-induced diplopia","volume":"46","author":"Dorell","year":"2005","journal-title":"Psychosomatics"},{"issue":"3","key":"10.3233\/JRS-210018_ref13","first-page":"45","article-title":"Diplopia; an Adverse Effect of Citalopram","volume":"5","author":"Hosseini","year":"2019","journal-title":"Pharm Biomed Res"},{"issue":"1","key":"10.3233\/JRS-210018_ref14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2190\/PM.49.1.h","article-title":"Seeing double: sertraline and diplopia: A case report","volume":"49","author":"Alao","year":"2015","journal-title":"Int J Psychiatry Med"},{"issue":"2","key":"10.3233\/JRS-210018_ref15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.5455\/bcp.20160109124021","article-title":"Sertraline-induced diplopia","volume":"26","author":"Eray","year":"2016","journal-title":"Bull Clin Psychopharmacol"},{"issue":"2","key":"10.3233\/JRS-210018_ref16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3233\/JRS-140616","article-title":"Ninety-three cases of alcohol dependence following SSRI treatment","volume":"26","author":"Brookwell","year":"2014","journal-title":"Int J Risk Saf Med"},{"issue":"3\u20134","key":"10.3233\/JRS-210018_ref17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3233\/JRS-180744","article-title":"Enduring sexual dysfunction after treatment with antidepressants, 5\u03b1-reductase inhibitors and isotretinoin: 300 cases","volume":"29","author":"Healy","year":"2018","journal-title":"Int J Risk Saf Med"},{"issue":"2","key":"10.3233\/JRS-210018_ref18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.3233\/JRS-210018_ref20","unstructured":"FDA Adverse Event Reporting System (FAERS). Accessed 26 June 2020 via openFDA."},{"issue":"4","key":"10.3233\/JRS-210018_ref21","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/JCP.0000000000000356","article-title":"Dry eye related to commonly used new antidepressants","volume":"35","author":"Ko\u00e7er","year":"2015","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"10.3233\/JRS-210018_ref22","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2165\/00023210-200418080-00001","article-title":"SSRIs and intraocular pressure modifications: Evidence, therapeutic implications and possible mechanisms","volume":"18","author":"Costagliola","year":"2004","journal-title":"CNS Drugs"},{"issue":"6","key":"10.3233\/JRS-210018_ref23","doi-asserted-by":"crossref","first-page":"e692","DOI":"10.4088\/JCP.15m10038","article-title":"Association of selective serotonin reuptake inhibitor use and acute angle-closure glaucoma","volume":"77","author":"Chen","year":"2016","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.3233\/JRS-210018_ref24","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/WCO.0000000000000523","article-title":"Visual snow syndrome: What we know so far","volume":"31","author":"Puledda","year":"2018","journal-title":"Curr Opin Neurol"},{"issue":"2","key":"10.3233\/JRS-210018_ref25","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00228-020-02996-9","article-title":"Visual snow syndrome after start of citalopram-novel insights into underlying pathophysiology","volume":"77","author":"Eren","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.3233\/JRS-210018_ref26","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2165\/11533180-000000000-00000","article-title":"Ocular adverse effects of common psychotropic agents: A review","volume":"24","author":"Richa","year":"2010","journal-title":"CNS Drugs"},{"issue":"4","key":"10.3233\/JRS-210018_ref27","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2174\/157015908787386104","article-title":"Selective serotonin reuptake inhibitors: A review of its effects on intraocular pressure","volume":"6","author":"Costagliola","year":"2008","journal-title":"Curr Neuropharmacol"},{"issue":"5","key":"10.3233\/JRS-210018_ref28","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1055\/s-2007-986237","article-title":"Palinopsie nach Absetzen von Venlafaxin [Palinopsia following discontinuation of venlafaxine]","volume":"35","author":"Spindler","year":"2008","journal-title":"Psychiatr Prax"},{"issue":"4","key":"10.3233\/JRS-210018_ref29","doi-asserted-by":"crossref","first-page":"368","DOI":"10.4088\/JCP.v63n0415c","article-title":"Palinopsia and paroxetine withdrawal","volume":"63","author":"Terao","year":"2002","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10.3233\/JRS-210018_ref30","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00004714-200004000-00027","article-title":"Unilateral facial numbness and visual blurring associated with paroxetine discontinuation","volume":"20","author":"Strickland","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"10.3233\/JRS-210018_ref31","doi-asserted-by":"crossref","first-page":"m754","DOI":"10.1136\/bmj.m754","article-title":"Post-SSRI sexual dysfunction","volume":"368","author":"Reisman","year":"2020","journal-title":"BMJ"},{"issue":"4","key":"10.3233\/JRS-210018_ref32","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/02713683.2017.1420198","article-title":"Effects of selective serotonin reuptake inhibitors on macular ganglion cell complex thickness and peripapillary retinal nerve fiber layer thickness","volume":"43","author":"Guclu","year":"2018","journal-title":"Curr Eye Res"}],"container-title":["International Journal of Risk &amp; Safety in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JRS-210018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:45:23Z","timestamp":1777509923000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JRS-210018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,22]]},"references-count":30,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jrs-210018","relation":{},"ISSN":["0924-6479","1878-6847"],"issn-type":[{"value":"0924-6479","type":"print"},{"value":"1878-6847","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,22]]}}}